Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Max Lataillade"'
Autor:
Judith A. Aberg, Bronagh Shepherd, Marcia Wang, Jose V. Madruga, Fernando Mendo Urbina, Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy N. Kumar, Eduardo Sprinz, Margaret Gartland, Shiven Chabria, Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 9, Pp 2321-2335 (2023)
Abstract Introduction Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) adults failing their cur
Externí odkaz:
https://doaj.org/article/8218d8a5b6c34c1bb1da2843ae2d87e4
Autor:
Ying Zhang, Mark Bush, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Brian R. Wynne, Samit Joshi, Max Lataillade
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 6, Pp n/a-n/a (2023)
Abstract GSK3640254 (GSK'254) is a novel HIV‐1 maturation inhibitor with pharmacokinetics supporting once‐daily (QD) therapy for HIV‐1 treatment. This thorough QT/corrected QT (QTc) study evaluated the effect of GSK'254 on cardiac repolarizatio
Externí odkaz:
https://doaj.org/article/5191d91a05ac43c2a70b1bf6d821069a
Autor:
Samit R. Joshi, Disala Fernando, Stephanie Igwe, Litza McKenzie, Anu S. Krishnatry, Fiona Halliday, Joyce Zhan, Thomas J. Greene, Jianfeng Xu, Geraldine Ferron‐Brady, Max Lataillade, Sherene Min
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Abstract Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure. Hence, there is a continuing demand for antiretroviral agents (ARVs) with novel mecha
Externí odkaz:
https://doaj.org/article/cb56c5de98f44634b415509c7f6e6e7f
Autor:
Ira Dicker, Sharon Zhang, Neelanjana Ray, Brett R Beno, Alicia Regueiro-Ren, Samit Joshi, Mark Cockett, Mark Krystal, Max Lataillade
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0224076 (2019)
GSK3532795 (formerly BMS955176) is a second-generation maturation inhibitor (MI) that progressed through a Phase 2b study for treatment of HIV-1 infection. Resistance development to GSK3532795 was evaluated through in vitro methods and was correlated
Externí odkaz:
https://doaj.org/article/3b995319e0514af1ae5adab6ab9b72a9
Autor:
Javier Morales-Ramirez, Johannes R Bogner, Jean-Michel Molina, Johan Lombaard, Ira B Dicker, David A Stock, Michelle DeGrosky, Margaret Gartland, Teodora Pene Dumitrescu, Sherene Min, Cyril Llamoso, Samit R Joshi, Max Lataillade
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205368 (2018)
GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor targeting a specific Gag cleavage site between capsid p24 and spacer peptide 1 of HIV-1. Study 205891 (previously AI468038) investigated the efficacy, safety, and d
Externí odkaz:
https://doaj.org/article/92a64a7f2d8649a182aebceafe35e801
Autor:
Shaili Gupta, Max Lataillade, Tassos C. Kyriakides, Jennifer Chiarella, Elizabeth P. St. John, Suzin Webb, Elizabeth A. Moreno, Birgitte B. Simen, Michael J. Kozal
Publikováno v:
Viruses, Vol 6, Iss 9, Pp 3428-3437 (2014)
Low-frequency HIV variants possessing resistance mutations against non‑nucleoside reverse transcriptase inhibitors (NNRTI), especially at HIV reverse transcriptase (RT) amino acid (aa) positions K103 and Y181, have been shown to adversely affect tr
Externí odkaz:
https://doaj.org/article/72b1b677385548378c718c5cbc684a9c
Autor:
Zeyu Lin, Joseph Cantone, Hao Lu, Beata Nowicka-Sans, Tricia Protack, Tian Yuan, Hong Yang, Zheng Liu, Dieter Drexler, Alicia Regueiro-Ren, Nicholas A Meanwell, Mark Cockett, Mark Krystal, Max Lataillade, Ira B Dicker
Publikováno v:
PLoS Pathogens, Vol 12, Iss 11, p e1005990 (2016)
HIV-1 maturation inhibitors (MIs) disrupt the final step in the HIV-1 protease-mediated cleavage of the Gag polyprotein between capsid p24 capsid (CA) and spacer peptide 1 (SP1), leading to the production of infectious virus. BMS-955176 is a second g
Externí odkaz:
https://doaj.org/article/a90b160f045e49bcad42a4f0b6eb0ad7
Autor:
Max Lataillade, Jennifer Chiarella, Rong Yang, Michelle DeGrosky, Jonathan Uy, Daniel Seekins, Birgitte Simen, Elizabeth St John, Elizabeth Moreno, Michael Kozal
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30118 (2012)
It is unknown whether HIV-positive patients experiencing virologic failure (VF) on boosted-PI (PI/r) regimens without drug resistant mutations (DRM) by standard genotyping harbor low-level PI resistant variants. CASTLE compared the efficacy of atazan
Externí odkaz:
https://doaj.org/article/26adf67fd8fc4adaaab99d6ab3617dd8
Autor:
Max Lataillade, Jennifer Chiarella, Rong Yang, Steven Schnittman, Victoria Wirtz, Jonathan Uy, Daniel Seekins, Mark Krystal, Marco Mancini, Donnie McGrath, Birgitte Simen, Michael Egholm, Michael Kozal
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e10952 (2010)
CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with tenofovir-emtricitabine in ARV-naïve subjects from 5 continents.Determine the baseline rate and clinical significance of TDR mutations using ultr
Externí odkaz:
https://doaj.org/article/8375a24f827a4f72b10609d3e67974e1
Autor:
Ying Zhang, Mark Johnson, Samit Joshi, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Martin Gartland, Max Lataillade
Publikováno v:
British Journal of Clinical Pharmacology.